Antibe signs distribution agreement with Acbel for ATB-346 drug
Pharmaceutical Technology | February 27, 2017
Antibe Therapeutics has signed a licensing and distribution agreement with Laboratoires Acbel for the drug ATB-346 in Greece, Romania, Serbia, Bulgaria, Albania, Algeria and Jordan. Anti-inflammatory drug ATB-346 has been designed to spare the gastrointestinal tract of the ulcers and bleeding normally associated with non-steroidal anti-inflammatory drugs (NSAIDs).